Indonesia approves Moderna's COVID-19 jab for emergency use

  • Indonesia has authorized Moderna's (NASDAQ:MRNA) COVID-19 vaccine for emergency use.
  • The country will receive 4M vaccine doses as part of the COVAX global-sharing scheme.
  • In addition, The Netherlands will also donate 3M vaccine doses, said Indonesian Foreign Minister Retno Marsudi.
  • Recently, Thailand also imported nearly 4M doses of Moderna's mRNA coronavirus vaccine.

    For this year the company, located in Cambridge revenue will be around 18.48 billion USD. This is according to the average of the analysts' estimates. This is hugely lower than 2020's revenue of 803.4 million USD.

    Historical revenues and results Moderna Inc plus estimates 2020

    fundamantele data

    The analysts expect for 2021 a net profit of 10.23 billion USD. The majority of the analysts expects for this year a profit per share of 24.82 USD. The price-earnings-ratio equals 10.46.

    For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is an attractive 1.97 percent.

    Based on the current number of shares Moderna Inc 's market capitalization equals 87.39 billion USD. The Moderna Inc stock was the past 12 months quite unstable. Since last July the stock is even 217 percent higher. This year the stock price moved between 54 and 261 dollar.

    Price data Moderna Inc 2007-2021

    financial analysis modernainc

    On Thursday the stock closed at 259.68 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.